August 26, 2015 | Researchers at Memorial Sloan Kettering Cancer Center have published the results of a Phase II trial to extend the indications for cancer therapy Zelboraf, in a "basket trial" protocol that divides patients by key biomarkers, discovering new molecular traits that may set apart patients likely to respond to treatment. FierceBiotech